✦ LIBER ✦

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Scribed by Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; Frans Van de Werf; Paul Armstrong; Gilles Montalescot; James Gilbert; John T. Strony; Robert M. Califf; Eugene Braunwald

Book ID: 116190175
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 148 KB
Volume: 149
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2005.03.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early use of glycoprotein IIb/IIIa inhib

Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiative

✍ Francis M Fesmire; Eric D Peterson; Matthew T Roe; James F Wojcik 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 236 KB

Randomized evaluation of the safety and

Randomized evaluation of the safety and efficacy of enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

✍ S.G. Goodman; D. Fitchett; P.W. Armstrong; M. Tan; A. Langer 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Randomized evaluation of the efficacy of

Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial

✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Impact of Gender and Antithrombin Strate

Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)

✍ Alexandra J. Lansky; Roxana Mehran; Ecatarina Cristea; Helen Parise; Frederick F 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 376 KB

Enoxaparin vs. unfractionated heparin in

Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-Segment elevation acute coronary syndromes managed with an intended early invasive strategy—primary results of the SYNERGY randomized trial

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Design and rationale of the MICHELANGELO

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 758 KB